[ad_1]
The first transplantation of stem cells to patients with multiple sclerosis was conducted in Italy and was successful. The infused patients had no side effects: they are individuals suffering from the most brutal form of the disease, called "progressive secondary", which does not have many therapeutic arms. The transplant was directed and announced by the scientific director of Revert Onlus, dr. Angelo Vescovi [VIDEO] director of Casa Sollievo della Suffering Hospital of San Giovanni Rotondo, in the province of Foggia. The hospital is one of the main points of reference in Italy for the research and treatment of neutrodegenerative diseases in addition to those of genetic origin.
The dr. Vescovi is one of the pioneers of research using brain stem cells and already in 2012 had begun to prepare stem cell transplants to treat such diseases by first treating the Sla, the amyotrophic lateral sclerosis . 19659004] Secondary progressive multiple sclerosis
Experiments on secondary progressive multiple sclerosis were initiated in collaboration with the ASL, the Terni Stem Cells Foundation, the Swiss Institutes of Research and the Hospital of Lugano. The three interventions were then performed by infusing 5 million stem cells into the lateral ventricle cavity and here they were able to diffuse through cerebrospinal fluid throughout the CNS. The physical execution of the grafts was entrusted to a competent neurosurgeon, Dr.
Sandro Carletti of the Department of Neuroscience of the Terni Hospital. The doctor. The bishops are very pleased with the result of the infusions which represent only one of the first stages of the most complete experimentation that his team is about to implement.
Researchers are now waiting for authorizations to implant stem cells in 15 other patients, in order to better observe the safety and tolerability of treatment. The group of patients waiting for infusion is between 18 and 60 years of age and will likely have more transplanted stem cells . In fact, it will increase from 5 to 10 million to increase again in the immediate future. In the meantime, numerous monthly and annual controls are planned for transplant patients whose surveillance will be extended until 5 years after surgery.
This article has been verified with:
- http://www.ansa.it/puglia/notizie/2018/06/27/ansa-staminali-su-primi-3-pazienti-con-sclerosi-multipla_120f39ac-c084-4458-b355-8f2e5297b424.html
- http://www.repubblica.it/salute/medicina-e-ricerca/2018/06/27/news/staminali_un_altra_sperimentazione_sulla_sclerosi_multipla-200215779/
Source link